Industry Calls on FDA To Relax Pediatric Device Requirements
This article was originally published in The Gray Sheet
Device company representatives want FDA to make changes to the humanitarian device exemption process and provide other incentives to pediatric device developers.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.